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ONecifts. The purpose of this study was to investigate the
blologle elcacy and pharmacokineties of different doses of recom •
bleat hirudin administered In single or repeated subcutaneous
hgjeetion` In healthy volunteers.
B bell Hlrodin Is a highly specific inhibitor of thrombin,
the pivotal enzyme In thrombosis . Differences between hirudin
and-Aeparta-In experimental animals Indicate that hirudin may be
a superior anilthrombodc drug in humans .
Mckeil. The biologic effect of recombinant desulfato•hirudin
(CGP 39393) added as single or repeated (every 8 h for 3
days or every 12 h for 6 days) subcutaneous Injections was studied
In 231 healthy human volunteers .
Resu&r. Single subcutaneous doses of 0.1, 0.2, 0.3, 0.4, 0.5 and
0.75 mg/kg body weight In 195, 8, 12, 8, 4 ad 4 volunteers,
respectively, prolonged the activated partial thromboplastin time
In a doee•propordonal fashion within the 1st 30 min, with a
marovuldmol effect for 3 to 4 hatter the dose . The mean activated
partial Ntromboplastht time Increased to 1 .48 and 1 .93 times
baseline values 30 ado Air single subcutaneous Injections of 0.2
and 0.4 mg/kg of CGP 39393, respectively . There was a linear
relatdel over a wide range between the activated partial thrum•
bopis tin lime prolongation and plasma concentrations of CGP
COP 39393 (recombinant desulfato-hirudin HVI) is produced
in yeast by recombinant deoxyribonucleic acid (DNA) tech-
nology using a chemically synthesized gene . It is identical in
structure and amino acid sequence to hirudin variant 1, the
naturally occurring anticoagulant of the leech Hirudo medic-
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39393. Plasma clearance was between 1 .5 and 1 .7 milmin per kg.
The subcutaneous administration of 0 .3 and 0.5 mg recombinant
hirudin three times a day for 3 days or two times a day for 6 days
prolonged the activated partial thromboplastin time by 1 .71 to
1.69 and 1.78 to 1.92 times baseline levels, respectively, with the
prefnjectlon values maintained in the hypocoagulable range . No
prolongation of bleeding time was measured at peak plasma
hirudin levels. Because thrombin and prothrombln times are not
able to reflect high or low CGP 39393 concentrations, respectively,
neither test is suitable for monitoring administration of this drug .
Co,wlusiwrs. CGP 39393 appears to be well tolerated in
volunteers, even after repeated doses. The activated partial
thromboplastin time test seem to be well suited to monitor the
anticoagulant effect of recombinant hirudin because the dose effect
is linear up to 0.5 mg/kg of subcutaneous CGP 39393 . The
prolongation
or activated partial thromboplastin time after sub•
cutaneous injection of CGP 39393 shows a plateau lasting for 3 h .
Further studies are now required to determine the dose that wilt
provide the best antithrombotic effect and the lowest bleeding
tendency in arterial or venous thrombosis indications .
(j Am Coll Carrdol 1993;22:1080-8)
inalls, except for the lack of a sulfato group on tyrosine 63
(1,2). Evaluation of rug) 39393 in various experimental
models has demonstrated its anticoagulant, antiplatelet and
antithrombotic properties . In vitro in human plasma and ex
vivo after ascending intravenous or subcutaneous doses in
rats, the dose-response curve exhibits linearity over a range
greater than that observed for standard, unfractionated
heparin (3) . The activated partial thromboplastin time pro-
longation persists for approximately I h after intravenous
administration (0.3 mg/kg body weight) and for 2 h after
subcutaneous administration (3 .0 mg/kg). In nephrectomized
rats, the intravenous duration of the anticoagulant action is
prolonged to at least 4 h (4) . In the shunt thrombosis model
in the rat ;5), CGP 39393 can completely inhibit thrombus
formation ; intravenous doses of 0.3 mg/kg and subcutaneous
doses of 1 mg/kg reduce thrombus weight by 50% (3). The
antithrombotic effect correlates almost linearly with the
0735-1G97/931$6 .00
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anticoagulant effect measured by activated partial thrombo-
plastin time, so that full antithrombotic efficacy is achieved
at, for example, a 3 .5- to 4-fold prolongation of the activated
partial thromboplastin time after subcutaneous administra-
tion (4) . Heparin exhibits less linearity in this correlation . In
the rat model of venous thrombosis (systemic hypercoagu-
lability induced by intravenous thromboplastin C with infe-
rior vena cava ligation), CGP 39393 has a median infective
dose of 0.01 mg/kg intravenously and 0 .45 mg/kg subcutane-
ously (3,4) . These results are in line with those obtained with
another recombinant hirudin used in a cardiopulmonary
bypass model (6) .
The role of thrombin in platelet-mediated thrombosis has
been demonstrated in several species, including the baboon
(7), the dog (8), the rabbit (9), the pig (10,11) and the hamster
(12). Recombinant hirudin reduced platelet-mediated throm-
bus formation in deep arterial injuries in pigs ; the antithrom-
botic activity correlated with the prolongation of the acti-
vated partial thromboplastin time but not the thrombin time
(13) . A similar conclusion was reached for recombinant
hirudin in a hamster platelet-rich mural thrombosis model
(14) .
Sufficient amounts of CGP 39393 are now available, and a
series of studies were carried out to investigate and evaluate
the biologic efficacy of different doses of subcutaneous CGP
39393 and to characterize the pharmacokinetic profile of the
drug administered in single or repeated subcutaneous injec-
tions. That COP 39393 is well tolerated in volunteers, even
after repeated doses, is being reported (15) .
Methods
Blood sampling . Blood for activated partial thromboplas-
tin time, prothrombin time, thrombin time, thrombin chro-
mogenic assay and recombinant hirudin assay was collected
in tubes containing sodium citrate before and 30, 60, 90,120,
150 min and 3, 4, 5, 6, 8 and 24 h after injection . Blood for
platelet count was collected in a tube containing ethylenedi-
amine tetraacetic acid .
Activated partial thromboplastin time . This test was per-
formed in duplicate in trisodium citrated plasma (1 :9 ratio)
with either an automated KC-4 or KC-10 coagulometer
(Amelung Lemgo) working within a preset range of values
(0 to 180 s) . The reagent Pathromtin (Behringwerke AG) was
used in all centers as a source of phospholipids . The normal
range is 28 to 40 s .
Thrombin time. To obtain different sensitivities for
thrombin time response, bovine thrombin was used at two
concentrations (3 and 6 IU/ml); 0.1 ml of platelet-poor
plasma and 0 .1 ml of diethylbarbiturate acetate buffer solu-
tion were incubated for I min at 37°C, and 0 .1 ml of thrombin
solution was added . Commercial test thrombin (Behring-
werke AG) and the automated KC-4 or KC-10 coagulometer
were used . Normal values are 14 to 21 and 8 to 13 s for the
lower and higher thrombin concentrations, respectively .
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Prothrombin time . The addition of tissue extract and an
excess of calcium to plasma initiates clottit . Commercial
tissue extract was added to the citrated plas'aa, and the
clotting time was recorded .
Thrombin chromogenic P;say. CGF 393G3 activity was
measured within 4 h of blood samplinr, according to a
modification of the method of Spannagl
Ft al . (16). Briefly, I
ml of buffer containing 0 .3 IU of thrombin (Behringwerke
AG), 5.0 kallikrein inhibitor units/mml of aprotinin (Bayer AG)
and 100 ng/nil of protamine chloride were added to 50
JA of
sample (probe or standard) . This was incubated at 25°C for
2 min, and then 100 µl of Chroraozym TH (1.9 mmol/liter)
(Boehringer) was added . The change in absorbance was
measured at 405 nm .
COP 39393 was added to immunocontrol Plasma Normal
(Immuno AG) to obtain various concentrations of CGP
39393 standard (e .g ., 0, 50, 100, 200, 300, 400 and 500 ng/ml) .
The standard curve .vas linear (between 0 and 500 ng/ml) .
Samples with higher -oncentrations of CGP 39393 standard
(e .g ., 1,000, 2 .000 and 3,000 ng/ml) had to be diluted . Control
samples were obtained from the same test subject before the
first recombinant hirudin administration (time 0) . All mea-
surements were performed in duplicate on an EPOS photom-
eter . Results are expressed in nmol/liter (0 .1 mg of CGP
39393 equals 14 .36 nmol) .
Plasma levels of CGP 39393. A double-antibody sandwich
enzyme-linked immunosorbent assay (ELISA) developed at
Ciba-Geigy Ltd . measures free COP 39393 concentrations
(17) . A first monoclonal antibody fixed on wells recognizes
an epitope of CGP 39393, and a second biotin-covered
antibody bound to another site of CGP 39393 produced1 a
color when in the presence of a sufficient amount of enzyme
and a chromogenic substrate . The intensity of the color is
proportional to the concentration of CGP 39393 in the
sample . In plasma, the limit of quantitation and the limit of
detection are 1 .2 and 0.3 nmol/liter, respectively .
Bleeding time . Bleeding time was measured either ac-
cording to Ivy et al . (18) (normal values 180 to 420 s) or
Mielke et al. (19) using a Simpla .e Il (General Diagnostics)
with a normal range up to 480 s.
Protection of human subjects . The study protocols were
approved by the Ethical Committee of each participating
centers (see Appendix) . Written informed consent was ob-
tained from each volunteer before entry into the study .
Statistical analysis and pharmacokinetic calculations. All
tests were performed in duplicate . Areas under the plasma
concentration-time curve were calculated according to the
linear trapezoidal rule . Elimination half-life was calculated
by the adjustment of a double-exponential function to the
appropriate phases of the log-linear plasma concentration
profile (20) .
Trial drug . Recombinant desulfato-hirudin (COP 39393)
was supplied by Ciba-Geigy Ltd. It was produced and
purified in collaboration with Gen Therapeutica Vertriebs
GmbH & Co. The compound has the sequence of hirudin
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Table 1. Single Subcutaneous Dose
of CGP 39393
Dose (mg/kg)
AFrr (x baseline)
30 min after irjection
Mean
Median
Range
8 h alter injection
Mean
Median
Range
Mean maximal APTC
Time to reach mean maximal APTT (min)
TT with 6 IU of thrombin (s)
Maximal median
Rap
COP 39393 plasma concentration (nmoliliter)
•
variant I but lacks sulfate on tyrosine 63 . Its specific activity
is 12,000 antithrombin Ulmg protein .
Results
Biakgic t> y of a single dose of sabcute Moos CGP
39393 In healthy vdantee rs. A total of 184 healthy volun-
teers not previously exposed to hirudin received two single
subcutaneous doses of 0 .1 mglkg of CGP 39393 injected
I month apart . The activated partial thromboplastin time
was prolonged from a mean ± SD of 37.2 ± 6.2 s before to
50.4 ± 9.2 s 2 h after the first injection and from 37,1 ± 3 .9 s
to 51 .1 ± 7.2 s I month later. None of the volunteers -it any
time reported an allergic reaction .
>siologLc ethcacy of different doses of subcutaneous CGP
303 in healthy vohtMeers . The biologic efficacy and toler-
ability of different dose levels of CGP 39393 were investi .
gated in 23 healthy, nonatopic volunteers previously never
exposed to hirudin Each subject received two different
single dose levels of COP 39393 separated by 2 to 34 days .
The first group of four volunteers received 0 .1 mg/kg of CGP
39393. Volunteers in subsequent groups of four could start
with the next higher dose (0.2, 0.3, 0.4, 0.5 or 0 .75 mg/kg)
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1 wo.step thrombin chromogenic assay
. AP IT = activated partial thromboplastin time ; CGP 39393 = recombinant desulfato-hirndin ; TT = thrombin time .
only after results of the lower dose were known . Volunteers
were followed up for 24 h after each subcutaneous injection
but could be discharged earlier from the clinical pharmacol-
ogy unit provided that the activated partial thromboplastin
time had returned to within 20% of the baseline vahie .
After subcutaneous injection, CGP 39393 is rapidly ab-
sorbed: at 30 min after dosing, the median prolongation of
the activated partial thromboplastin time was dose propor-
tional (Table 1) . Mean activated partial thromboplastin time
was prolonged in a dose-related manner (Fig . I) . The maxi-
mal effect of activated partial thromboplastin time was
maintained until approximately 3 to 4 h after dosing, after
which activated partial thromboplastin time levels gradually
declined to near baseline . The mean levels by 8 h after
dosing were still slightly prolonged for doses ?0.3 mg/kg
(Table I). Although the effect on activated partial thrombo-
plastin time at higher doses of recombinant hirudin was
maintained slightly longer, the mean activated partial throm-
boplastin time values had returned by 24 h to approximately
baseline values for all dose levels tested .
A dose-related prolongation of the thrombin time up to
0.4 mg/kg of CGP 39393 was apparent when the test was
performed with 6 IU of thrombin/ml (Table 1) . The effect on
0 .1
(n = 11)
0.2
(n = 81
0.3
(n -
12)
0 .4
(n
-
8)
0.5
(n = 4)
0.75
(n = 4)
1.39
1 .48 1 .74 1 .93 i .6:
2.03
1 .35 1 .46 1 .67
1,96 1 .58 2.01
1 .24-1 .60 1 .7-164 1 .37-2 .16
1 .61-2 .32 1 .42-1 .96 1 .78-2 .30
1.14
1 .10 1 .24 1 .24 1 .59 1 .61
1
.06 1 .07 1 .20 1 .25 1 .53 1 .60
0 .91-1 .45 0.96-1 .24 1 .10-1 .40 0 .95-1
.45 1
.33-2.04
1 .51-1 .72
1 .43 1 .57 1 .77
1 .81
1 .75
2.05
90 60 60
60 240 60
12 .4
19.9 27 .2 36 .0 27 .7 Out of range
10
.5-15 .1 11 .9-32.0 14.7-45 .0 18.2-45.0 13,8-60 .9
30 min alter in)ection
Mann
14 .8
20.2
42.5
41 .2 28 .1 65.1
Median 10.1
20.3 40.1 40 .4 26 .7 60.5
Rup
7.4-32 .0 9.3-37 .3 14 . :x71 .4 32 .0-55 .0 20.4-38 .5 50.3-89j
8 h after itjection
Mean
5 .1 4.0 15 .8 9 .0 29 .9 33.2
Median 5.1 0
15 .1 9
.2
29.8 32.9
Range 1 .5-9.2
0-22 .0 8.1-27.2 4 .0-15 .8 25 .1-34 .9 23 .6-43 .5
24 h after injection
Mean
0.2 0.8 0.2 0 5.2 0.8
Median 0 0 0 0 5.7 0.8
Range 0-0.6
0-6
.2
0-0.6 0-0 2
.9-6.7
0-1
.6
Mean peak concentration
19 .9 32 .7 39.8 53.6 37 .3 81 .1
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thrombin time was apparent within 30 min . It was maximal at
approximately 2 to 3 h after injection and by 4 h had returned
to near-baseline values . Higher doses of CGP 39393 had a
maximal effect 4 to 8 h after injection and returned to
baseline after 12 to 24 h . The prothrombin time remained
essentially unchanged at any concentration used .
Changes in the plasma concentration of CGP 39393 (two-
step thrombin chromogenic assay method) were dose re-
lated, with peak levels within 30 to 120 min after injection at
all dose levels (Table 1) . High plasma concentrations were
maintained until approximately 3 h after dosing up to
0.4 mg/kg and 4.8 h after higher dosing, with a return to
near-baseline values by 24 h . As assessed by the immuno-
logic method, the concentrations of CGP 39393 were on
average 1 .7 times those obtained with the functional method .
Single subcutaneous injections of recombinant hirudin
displayed dose-proportional, linear kinetic effects (immuno-
logic assay) (Table 2) . Intersubject variation of the high-
est observed dose-normalized concentration (measured by
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Figure 1. Activated partial thromboplastin time (API) measured
at different time intervals after a single subcutaneous injection of
recombinant desulfato-hirudin (CGP 39393) : 0.1 mgfkg body weight
(195 volunteers), 0 .2 mg/kg (8 volunteers), 0 .3 mgfkg (12 volunteers)
and 0.4 mg/kg (8 volunteers) .
ELISA) (Cmax) and the area under the plasnw concentration-
time curve (AUC) for doses 0.110.3 and 0 .210.1 mg/kg of CGP
39393 was 25% to 46%, about twice as large as intrasubjeet
variation (10% to 25%) . Dose-normalized Crnax and AUC
were independent of dose ; therefore the pharmacokinetic ef-
fects of CGP 39393 were linear.
There was a clear relation between the inhibition of
coagulation, measured as activated partial thromboplastin
time, and plasma concentrations of CGP 39393 (linear least-
squares regression analysis; r = 0.8399, n = 334) (Fig. 2).
The activated partial thromboplastin time extends in a linear
manner over the whole range of hirudin plasma levels,
whereas the thrombin time does not (Fig . 2) .
*CGP 39393 ; relative molecular mass 6,964 ;1 mg corresponds to 143 nmol . AUC
- area under the concentration-time curve in the interval 0-24 h . calculated
by the linear trapezoidal rule; C1= clearance, calculated as dose/AUC, assuming bioavs'lability to be 100%
: Cmax = highest observed concentration (measured
by enzymo-finked immunosorbent assay) ;Tmax = time to reach Cmax .
Dose (mg/kg)
0.1(n=11) 0.2 (n=8) 0.3(n=12) 0.4 (n=81 0 .5 (n =4) 0
.75 (n=4)
Mean So Mean SD Mean SU Mean SD
Mean SD Mean Sit
Cmax (nmol/lte0 21 .1 9.1 57 .9 17 .6 64 .2 30.5 93.4 18.5
47.9 14 .0 107 .€0 45 .0
Tmax (h) 2 .5 1 .0 1 .7 0.6 2 .2 0.7 1 .3 0.9 2 5 13 3 .0
1
.2
Median Tmax (h) 2 .5 1 .75 2 .25 1 .0
2.5 3.25
AUC (hlnmol per liter) 135 .0 37 .0 3041.1 48 .0 413 .0 I NA 575 .0 78 .0 509.0 72 .0
728
.0
90.0
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No clinically relevant changes in hemodynamic variables,
body temperature or routine clinical laboratory tests after
sul'cutane : us injection of up to 0
.75 mg/kg of CGP 39393
were noted
. One of the 24 volunteers briefly had mild
dizziness and tachycardia starting ft2 h after injection and
lasting 1 .5 h
. Three other volunteers each had a hematoma or
erythema or petechiae at the site of the injection
. No seriouv
systemic adverse reactions were reported, and none had skin
intolerance or allergic reactions to the two subcutaneous
injections of CGP 39393, separated by at least 2 to 34 days
.
Biologic Amy of subcutaneous Injections of two dose
With of CGP 39393 every 8 h to 3 consecutive days In healthy
vohweers. Sixteen healthy subjects, of whom 12 had been
previously exposed to CGP 39393 but maintained negative
responses on prick and intradermal tests, volunteered to
receive subcutaneous CGP 39393 administered every 8 h in
alternating sites of the abdomen for 3 consecutive days. Two
dose levels (0.3 and 0
.5 mg/kg) were studied sequentially in
two groups of eight subjects each
. They were followed up for
u
r
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Figure 2. Scatter plots of correlation
between activated partial throm-
boplastin time (APTT) (top) or
thrombin time (TT) (bottom) and
plasma concentration of recombi-
nant desulfato-birudin (COP 39393).
L = liter
; TCA - thrombin chromo-
genic assay .
•
r
•
.
a minimum of 16 h after the last injection of CGP 39393 or
longer if the activated partial thromboplastin time had not
returned to within 120% of the baseline value . Blood samples
were taken before and 1, 3 and 8 h after each subcutaneous
injection and 16 h after the last (eighth) injection . Bleeding
time, according to Ivy et al . (18), was measured just before
the first (baseline) and 3 h after the last injection of CUP
39393.
The mean age and weight of the 16 volunteers were
28.3 ± 2.8 years and 71 .1 ± 13.4 kg. After having recei%ed
the fourth subcutaneous injection of 0
.3 mg/kg of CGP
39393, one subject prematurely discontinued the study ow-
ing to moderate menstrual bleeding
. After the first adminis-
tration, the mean activated partial thromboplastin time was
prolonged to 74 .7 and 77
.3 s 3 h after 0.3 and 0.5 mg/kg,
respectively (Table 3) . By 16 h after the eighth and last
subcutaneous injection, the mean activated partial thrombo-
plastin time had returned to baseline values for the two dose
levels investigated .
JACC Vol. 22. No. 4
October 1993 :1080-8
Median thrombin time (test performed with 6 IU/ml
thrombin) was prolonged to between 18 .7 and 49.6 s 3 h after
injection of 0.3 mg/kg of CGP 39393. Maximal thrombin time
prolongation was obtained I h after the second injection
from a median of 10 .2 s at baseline to a median of 66 .3 s
(range 13 .7 to 176). All thrombin time values returned to
baseline 16 h after the last subcutaneous administration of
COP 39393 (0.3 and 0.5 mg/kg) .
Prothrombin times were only marginally influenced by
the tyro dose levels of COP 39393, and platelet counts
remained within the normal range (> 150,000/mm3) through-
out the study. Three hours after the eighth subcutaneous
injection of recombinant hirudin, one volunteer at each dose
level had a bleeding time outside the normal values (450 and
630 s,
respectively).
Spurious changes in platelet count or
bleeding time do not appear to be related to the concentra-
tions of COP 39393 measured by ELISA .
Biologic eitleacy of subcutaneous injections of two dose
levels of CGP 39393 every 12 h for 6 consecutive days in
kenlthy volunteers. There ware four volunteers for each
dose (0.3 and 0.5 mglkg) of COP 39393, and the subcutane-
ous injections were given every 12 h for 6 consecutive days .
Blood was sampled before and 3 and 12 h after each injection
and 16 and 36 h after the last (12th) one . Bleeding time was
measured with the Mielke method before the first and 3 h
after the last injection .
After the first injection, the mean activated partial throm-
boplastin time was prolonged to 56.1 s (1 .67 times baseline)
and 64.0 s (2 .01 times baseline) for the 0.3- and 0.5-mg/kg
doses, respectively (Table 3) . Twelve hours after the first
dosing, the mean activated partial thromboplastin time for
the two dose levels was 1 .04 and 1.47 times the mean
baseline values, respectively . By 16 and 36 h after the last
injection, the mean activated partial thromboplastin time had
returned to baseline value for the 0 .3-mg/kg dose . For the
0.5-mg/kg dose level, the mean activated partial thrombo-
plastin time was still slightly prolonged (1 .27 times baseline)
after 16 h but had returned to nearly baseline at 36 h .
Median thrombin time (test performed with 6 IU/ml of
thrombin) was prolonged to 19.8 s (range 12.7 to 31 .5) 3 h
after the first 0 .3-mglkg injection. Maximal thrombin time
prolongation was obtained after the ninth subcutaneous dose
from a median of 10 .2 s at baseline to a median of 25 .3 s
(range 18.0 to 40.8). Seventy-five percent of the thrombin
time values were prolonged >200 s (beyond the working
limits of the automated coagulometer) 3 h after the first, third
and eighth injections of 0.5 mg/kg of CGP 39393. All throm-
bin time values returned to baseline 16 and 36 h after the last
subcutaneous administration of 0.3 or 0.5 mg/kg. The Mielke
bleeding times remained within the normal range .
Discussion
Single subcutaneous injection of CGP 39393 . The present
experience with COP 39393 completes previous reports
obtained with natural hirudin in humans (23,24). When
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tested in 184 healthy volunteers, the activated partial throm-
boplastin time was prolonged to almost twice the baseline
value 2 h after a single subcutaneous injection of 0 .1 mg/kg of
CGP 39393. The ituersubject coefficient of variation of the
weight-adjusted COP 39393 dose level remained within 20%
of the mean value, even when COP 39393 was readminis-
tered I month apart in these immunocompetent volunteers,
suggesting that COP 39393 did not elicit neutralizing anti-
bodies. When four dose levels were tested in four volunteers
-rtaining to one center (each volunteer receiving two
different doses), the mean activated partial thromboplastin
time was maximally prolonged 1 .42, '. .70, 1.75 and 2.05
times the mean baseline values for the 0.1-, 0 .3-, 0.5- and
0.75-mg/kg subcutaneous doses of COP 39393, respectively
.
Onset ofeffect occurred within the 1st 30 min of administra-
tion; a high concentration was sustained for 4 to 6 h after the
dose. Although the duration of the effect of activated partial
thromboplastin time was slightly longer at the higher doses,
the mean activated partial thromboplastin time Lad returned
to approximately baseline values for all four dose levels
tested by 24 h after single dosing. The prolongation of activated
partial thromboplastin time was related to plasma COP 39393
concentrations, whether measured by the functional or immu-
nologic method, even with the highest concentration con-
firming in vitro observations in rat plasma (3) . Doubling of
the activated partial thromboplastin time is obtained at circa
400 ng of COP 39393/ml of plasma (two-step thrombin
chromogenic assay method), which corresponds to approx-
imately 60 nmol/liter. Plasma clearance after subcutaneous
injection was between 1 .5 and 1 .7 rnllmin per kg, and
apparent elimination half-life was between 2 and 2 .4 h.
Repeated subcutaneous injections of CGP 39393. When
0.3 or 0.5 mg/kg of subcutaneous COP 39393 was injected at
8-h intervals for 3 consecutive days in 16 subjects, the mean
activated partial thromboplastin time prolongation, obtained
3 h after dosing, was dose dependent and ranged, respec-
tively, from 1 .67 to 1 .88 times baseline values . The activated
partial thromboplastin time changes are reproducible and are
again parallel with the concentrations of COP 39393 mea-
sured with an immunologic or functional assay. With three
times daily subcutaneous administration of CGP 39393 for 3
days, the mean activated partial thromboplastin time and
plasma concentrations of CGP 39393 remained elevated at
the end of each dosing interval. On the basis of activated
partial thromboplastin time prolongation and plasma concen-
trations of COP 39393, there is no suggestion of cumulative
pharmacodynamic and pharmacokinetic effects. Values re-
turned to baseline 16 h after the eighth subcutaneous injec-
tion, irrespective of the dose level . When the same two dose
levels were administered twice daily, the mean activated
partial thromboplastin time obtained 3 h after dosing was
dose dependent and ranged from 1 .5 to 2 .5 times baseline .
The activated partial thromboplastin time values for the
6-day administration of two dose levels of subcutaneous
COP 39393 administered every 12 hours are reproducible
and parallel with the changes in the plaima concentration of
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Table 3. Plasma
Concentration and Effect of Subcutaneous Injections of CGP 39393 on Activated Partial Thromboplastin Time
recombinant hirudin. Although with low and medium doses
the activated partial thromboplastin time prolongation
strongly correlates with the plasma drug concentration. it
increases less than proportionally with higher plasma con-
contrations or increasing doses,
Motiltvring of CGP 393!3, The thrombin time directly
reflects the inhibition of thrombin and is sensitive to low
concentrations of CGP 39393 . Mean concentrations between
30 and 40 nmollliter of recombinant hirudin (ELISA) were
shown to double the thrombin time, whereas the activated
partial thromboplastin time doubled by a concentration of
1.14 nmal/liter
. By reason of its effective range and simpfic-
AP'[T -
activated partial thromboplastin lime . EUSA = enzyme-(inked immunosorbent assay
.
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ity. activated partial thromboplastin time was chosen to
monitor the anticoagulant effect of CGP 39393 . These find-
ings are consistent with those previously reported in animals
(21,22) and in humans exposed to natural hirudin (23 -25) and
with in vitro experiments performed with recombinant hiru-
din (3,4,24) .
No clear prolongation of bleeding time was observed at
mean peak levels after 0 .3 and 0 .5 mg/kg of recombinant
hirudin. This suggests that the effect on primary hemostasis
is probably minimal, a finding that may be of considerable
importance should hirudin be used in the postoperative
period .
0 .3 mglkg
0
.5 mg/kg
8 Hourly 12 Hourly 8 Hourly 12 Hourly
Prolongation of AP`IT after first injection (x baseline)
3h
Mean
Lr,
1 .67 1 .77 2
.01
Median
1
.71 1 .69 1 .78 1 .92
Range
1 .63-2 .06 0.92-1 .10 1 .63-2.02 1 .76-2 .45
8h
Mean
1 .44 1 .38
Median
1 .43
1 .41
Raw
1
.32-1
.63 1 .14-1 .61)
12h
Mean
1 .04 1 .47
Median
1 .04 1 .52
Ran%*
0.98-1 .13 1 .17-1 .69
Maximal mean AP'Tf prolongation On day 3 after 7th
injection
On day 6 after I Ith
injection
On day 2
after 4th
it jcction
On day 4 after 8th
injection
Return of APTT to baseline alter last ijection thl if, 16-36 16 36
Conceniratktn of COP 39393 by ELISA InmoUlitcr) ;
time
after first injection
3h
Mean 65.7 44.2
88
.8 71 .1
Median 63.9 42.6 97.2 69.0
Range 55 .2-93 .0 33.0-58 .8 35 .5-119 .0 55.5-91 .7
8h
Mean 11 .6 27.7
Median 13 .0 23.8
Range 7.2-15 .8 9 .4-62 .4
12h
Mean
2 .5 139
Median 2 .4
14.7
Raw 0.8-1 .7 5.6-20.8
Mean (and corresponding median) peak concentration 93 .1 479 115 .1 79.2
of COP 39393 by ELISA (nmol/liter) (91 .4) (46 .01
1140
.51
(72 .01
Concentration or COP 39393 by ELISA (nmol(liter) .
lime
after last injection
16h
mean
1 .7
43 .8
Median
1 .3
20 .1
Range
0.33 .4 11 .2-163 .4
36 h
Mean
0 .1
0.1
median
0 .1 0.0
Range
0.0-0
.1 0
.0-0.5
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Safety and tolerability in volunteers. Tolerability and
safety measurements (physical examination, hemodynamic
variables, electrocardiogram, routine clinical chemistry and
hematologic values) were not influenced by administration of
repeated sulr'cutaneous doses of recombinant hirudin . The
activated partial thromboplastin time lest seems to be well
suited to monitor the anticoagulant effect because the dose
effect is linear up to 0 .5 mg/kg of CGP 39393 . The prolonga-
tion of activated partial thromboplastin time after subcutane-
ous injection of CGP 39393 shows a plateau lasting for 3 h . This
is consistent with the slow but nearly complete (85%) absorp-
tion from the site of injection reported by Bichler et al . (24).
Heparin and hirudin are potent inhibitors of thrombin, the
central enzyme in thrombosis ; hirudin, however, is a much
more selective thrombin inhibitor . There are several features
in favor of hirudin as an antithrombotic drug . In contrast to
heparin. hirudin is not inactivated by platelet factor 4,
histioine-rich glycoprotein or vitronectin, all proteins whose
levels are increased in some disorders, which can cause
hepudn resistance . Hirudin has no direct effect on platelets
and undothelial cells, whereas heparin does, and this may
contribute to the risk of bleeding and to heparin-induced
thrombocytopenia. Thrombin bound to fibrin or endothelium
is inactivated by hirudin but not by heparin ; hirudin is,
moreover, independent of antithrombin 111 . Hirudin may
thus be a better antithrombotic agent than heparin . Despite
the fact that the polypeptide hirudin comes from nonhuman
sources, it has the theoretic potential to be allergenic in
humans . Local immune reactions to subcutaneous adminis-
tration of recombinant CGP 39393 in 182 male or female
volunteers were not observed (15) . The clinical pharmacol-
ogy of intravenous bolus injections or infusions of CGP
39393 in healthy volunteers is being reported (26) .
Future directions. The results of this study in healthy
volunteers form a reasonable basis for further studies to
determine the optimal doses for the prevention of venous
and arterial thrombosis in high risk patients . Studies are
currently underway comparing recombinant hirudin with
standard heparin in the prevention of venous thrombosis
after hip surgery (27) . Because coronary reocclusion after
thrombolysis is still a problem, notwithstanding concomitant
administration of aspirin and intravenous heparin, hirudin is
being investigated to prevent early reocclusion and recurrent
myocardial infarction (28) . Because hirudin, in contrast to
heparin, inhibits thrombin bound to subendothelial extracel-
lular matrix and fibrin remnants, it is logical to explore the
effectiveness of hirudin in preventing reocclusion after per-
cutaneous coronary angioplasty (29) .
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